Bonita David P 4
4 · Prelude Therapeutics Inc · Filed Apr 23, 2026
Research Summary
AI-generated summary of this filing
Prelude Therapeutics (PRLD) 10% Owner Bonita David P Buys Stock
What Happened
Bonita David P, listed as a 10% owner, acquired a total of 2,815,315 shares of Prelude Therapeutics (PRLD) on April 21, 2026. The purchases were two lots of 1,689,189 shares and 1,126,126 shares, each priced at $4.44 per share, for aggregate proceeds of $7,499,999 and $4,999,999 respectively (total ≈ $12,499,998). These were purchases (P) — a direct buy rather than a sale.
Key Details
- Transaction date: 2026-04-21; Filing date (Form 4): 2026-04-23 (filed within the typical two-business-day window).
- Price per share: $4.44 for both lots.
- Shares purchased: 1,689,189 and 1,126,126 (total 2,815,315).
- Total disclosed purchase value: approximately $12.5 million.
- Footnote F1: Securities were purchased in an underwritten public offering (not an open-market trade).
- Footnotes F2–F4 & F5: Shares are held of record by OrbiMed funds (e.g., OrbiMed Private Investments VI, OrbiMed Partners Master Fund, OrbiMed Genesis Master Fund). Bonita David P is a member of OrbiMed Advisors; OrbiMed entities may be deemed to have voting/investment power but disclaim beneficial ownership except to the extent of any pecuniary interest.
- Shares owned after the transaction: not specified in the excerpted filing.
Context
This filing reports institutional/management-related purchasing through OrbiMed-affiliated vehicles (a 10% owner), not an individual executive's open-market trade. Purchases in an underwritten offering can reflect participation by existing investors or allocated investors rather than opportunistic open-market buying; the filing is factual and does not indicate motive.
Insider Transaction Report
Form 4
Bonita David P
Director10% Owner
Transactions
- Purchase
Common Stock
[F1][F2][F5]2026-04-21$4.44/sh+1,689,189$7,499,999→ 11,808,945 total(indirect: See footnotes) - Purchase
Common Stock
[F1][F4][F5]2026-04-21$4.44/sh+1,126,126$4,999,999→ 1,126,126 total(indirect: See footnotes)
Holdings
- 526,300(indirect: See footnotes)
Common Stock
[F3][F5]
Footnotes (5)
- [F1]These securities were purchased in an underwritten public offering.
- [F2]These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
- [F3]These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM.
- [F4]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
- [F5]Each of the Reporting Person, OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Signature
/s/ David P. Bonita|2026-04-23